Roche, the Swiss pharmaceutical company, has announced the acquisition of the American laboratory Carmot for 2.7 billion dollars.
Carmot specializes in developing products to treat obesity in people with and without diabetes, a growing problem, especially in Western markets such as the United States.
The agreement, which could reach a total of 3.1 billion dollars, including additional payments for achieving objectives, gives Roche access to products to treat obesity, either orally or intravenously.
These products are currently in clinical trial phase, according to Roche's statement.
Roche's decision is based on studies indicating that around 4 billion people, half of the world's population, could face obesity or overweight problems by 2035.
This phenomenon represents a growing health challenge, especially in developed countries, generating strong demand for healthcare products to combat it.
Information from: Forbes México.
Receive all industry news in our weekly Newsletter Scientific Dialectics.